Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - irinotecan hydrochloride trihydrate 20 mg/ml - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - dbl™ irinotecan injection concentrate is indicated as a component of first line treatment of patients with metastatic carcinoma of the colon or rectum. irinotecan injection concentrate is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - irinotecan hydrochloride trihydrate 20 mg/ml;  ;   - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml     excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

viatris limited - irinotecan hydrochloride trihydrate 20 mg/ml equivalent to 17.33 mg irinotecan;  ;   - concentrate for infusion - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml equivalent to 17.33 mg irinotecan     excipient: lactic acid sodium hydroxide sorbitol water for injection - irinotecan concentrate for infusion is indicated for the first line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with 5fu/leucovorin. irinotecan concentrate for infusion is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors